Originally published by our sister publication Infectious Disease Special Edition
The FDA expanded the indication for bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance.
HIV treatment resistance is permanent and irreversible, which can jeopardize future treatment options for PWH. The range of M184V/I resistance mutation in